Post-menopausal osteoporosis and acromegaly are skeletal disorders involving in different ways the osteogenic lineage, as well as osteogenesis imperfecta (OI), a heterogeneous genetic disorder characterized by osteopenia and bone fragility. This project aims to 1) pharmacologically target signalling pathways involved in osteogenic maturation of progenitor stem cells and 2) tailor personalized treatments based on ex vivo approaches. A new formulation of bioactive supplements (vitamin D, ascorbic acid, fisetin, folic acid, pigment epithelium derived factor=PEDF) will be assayed on pluripotent stem cells (PSC) either from peripheral blood (circulating PSC) of osteoporotic and acromegalic patients or on fibroblast-derived stem cells of young OI patients (iPSC).
